Drug Profile


Alternative Names: hE16; MGAWN 1; West Nile virus monoclonal antibody - MacroGenics

Latest Information Update: 03 Dec 2012

Price : $50

At a glance

  • Originator Washington University
  • Developer MacroGenics
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Viral envelope protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • Available For Licensing Yes

Highest Development Phases

  • Discontinued West Nile virus infections

Most Recent Events

  • 06 Nov 2012 Discontinued - Phase-II for West Nile virus infections in Canada (IV)
  • 06 Nov 2012 Discontinued - Phase-II for West Nile virus infections in USA (IV)
  • 01 Nov 2010 MacroGenics suspends phase II expanded access trial [NCT01206504] in West Nile virus infection in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top